Chlorhexidine: the most powerful dental antiseptic — and its cost

Chlorhexidine is one of the few cases in dentistry where the hype is earned. It genuinely works. It kills gram-positive bacteria, gram-negative bacteria, enveloped viruses, and certain fungi — and it keeps working for hours after you spit it out, because it binds to the surfaces in your mouth and releases slowly. This property — called substantivity — is what separates it from every other antiseptic rinse on the market.

Synthesised in 1954 as a surgical antiseptic, it moved into dentistry in the 1970s once researchers realized its sustained adhesion made it uniquely suited for oral use. By the 1990s it had become the gold standard against which every other mouthwash is benchmarked. That status is deserved. It's also incomplete.

The mechanism — and why it doesn't discriminate

Chlorhexidine is a bisbiguanide with two positively charged ends. It's attracted to the negatively charged surfaces of bacterial membranes. At low concentrations it disrupts osmotic balance, causing cells to leak. At high concentrations it ruptures the membrane outright. Because the mechanism is physical rather than biochemical, classical antibiotic resistance doesn't apply — there is no single receptor to mutate around.

This physical promiscuity is both the feature and the flaw. The human oral cavity hosts approximately 700 bacterial species. Among them are nitrate-reducing anaerobes — predominantly Bacteroidetes — whose ecological role is to convert dietary nitrate into nitrite within saliva. This nitrite then circulates and is converted into nitric oxide (NO) in the stomach, tissues, and bloodstream.

Nitric oxide is a vasodilator. It relaxes arterial walls, reduces peripheral vascular resistance, and helps regulate blood pressure. This circuit is called the enterosalivary pathway: dietary nitrate from vegetables like spinach, beetroot, and rocket → oral bacteria → salivary nitrite → systemic NO.

Chlorhexidine eliminates those bacteria efficiently. Very efficiently.

The clinical data — what the numbers actually show

Efficacy: real and well-documented. A 2017 Cochrane systematic review (James et al., 30 RCTs, meta-analysis of 13 trials, 1,100+ participants) found that chlorhexidine mouthrinses reduced the plaque index by SMD −0.35 (95% CI −0.48 to −0.22) and the gingival index by SMD −0.27 (95% CI −0.40 to −0.14). In plain terms: roughly 33% reduction in plaque, 26% reduction in gingival inflammation. These are clinically meaningful results. Tooth staining was also significantly increased — a brownish discoloration that doesn't rinse away with water.

The 0.12% vs 0.2% question: the difference is smaller than marketed. A 2010 meta-analysis (Van Strydonck et al., 7 trials) found a WMD of 0.10 (95% CI 0.03–0.17, p=0.008) in favour of 0.2% on plaque indices — statistically significant, clinically negligible. At equivalent efficacy, 0.12% produces fewer side effects.

The microbiome disruption: where it gets complicated. In 2020, Bescos et al. (Scientific Reports, Nature Publishing Group) conducted a randomised crossover trial with 36 healthy adults. Seven days of chlorhexidine mouthwash produced a measurable compositional shift: Firmicutes and Proteobacteria increased, Bacteroidetes declined. Salivary pH fell. Salivary and plasma nitrite levels dropped significantly (p<0.05). Oral nitrate reduction was suppressed by approximately 90%. A trend toward increased systolic blood pressure was observed — 2–3.5 mmHg across the group.

This wasn't a stressed population or patients with pre-existing disease. These were healthy adults, and a week of mouthwash was enough to disrupt a physiologically relevant systemic pathway.

Intensive care evidence: the stakes scale up. Blot et al. (Intensive Care Medicine, 2020) analysed 11 RCTs of chlorhexidine oral decontamination in ICU settings in a meta-analysis. The finding was uncomfortable: an association between CHX use and increased mortality (OR 1.25; 95% CI 1.05–1.50). The enterosalivary pathway suppression is among the proposed mechanistic explanations — critically ill patients may be particularly dependent on alternative NO-generating routes.

Antibiotic resistance genes: an unexpected finding. A 2024 study from the University of Freiburg (Bartsch et al., Frontiers in Microbiology) used 16S rRNA sequencing and found that chlorhexidine digluconate significantly increased the prevalence of tetracycline resistance genes in the oral microbiome (p<0.05). The mechanism is under investigation, but the selection pressure hypothesis is straightforward: a broad-spectrum antiseptic kills sensitive competitors and enriches resistant strains — even those not directly targeted.

Epidemiological signal: hypertension. In 2025, Schenkein, Loos et al. (Quintessence International) published a retrospective analysis of a large hospital cohort (October 2015 – May 2024, NIH's i2b2 platform, thousands of de-identified patients). Users with a history of chlorhexidine mouthwash had elevated odds ratios for a diagnosis of primary arterial hypertension. Observational data, not experimental — but it adds a population-level layer to a mechanism already demonstrated in the lab.

Bescos et al. (2024, Frontiers in Oral Health) directly compared propolis and chlorhexidine rinses: the 0.2% CHX solution reduced nitrite-producing bacteria significantly more than propolis (p<0.05), and the authors explicitly flagged the need for caution in hypertensive patients.

When to use chlorhexidine — and when to choose something else

The evidence converges on a clear practical position: chlorhexidine is a short-course clinical tool, not a daily maintenance product.

Appropriate uses:

• Acute gingivitis or periodontitis during active treatment (7–14 day course under dental supervision)
• Pre- and post-surgical oral decontamination
• Temporary inability to perform adequate mechanical hygiene (post-operative period, immobilisation)
• Orthodontic appliances that significantly complicate brushing

Where it is disproportionate or harmful:

• Daily "preventive" use in a healthy adult with intact oral hygiene
• Any use in hypertensive patients or those with cardiovascular risk factors without medical oversight — particularly 0.2% formulations
• Extended courses beyond two weeks without a defined clinical indication

What to use for daily prevention instead: Cetylpyridinium chloride (CPC) — a quaternary ammonium compound with proven antibacterial activity and a substantially different microbiome impact profile. Essential-oil-based rinses (thymol, menthol, eucalyptol, methyl salicylate) — comparable short-term efficacy with minimal tooth staining and no evidence of enterosalivary pathway suppression.

One practical note regardless of duration: don't rinse with chlorhexidine immediately after brushing with fluoride toothpaste. The two compounds form insoluble salts that reduce the effectiveness of both. Wait at least 30 minutes — or use CHX at a different time of day.

Chlorhexidine remains the best-studied, most consistently effective antiseptic in dentistry. That reputation is not going away. The emerging literature doesn't argue for retiring it — it argues for using it precisely, in defined windows, for defined purposes. The power is real. So is the price.

---

Sources:

1. James P, Worthington HV, Parnell C, et al. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev. 2017. DOI: 10.1002/14651858.CD008676.pub2 (PMID: 28362061)

2. Bescos R, Ashworth A, Cutler C, et al. Effects of chlorhexidine mouthwash on the oral microbiome. Scientific Reports. 2020. DOI: 10.1038/s41598-020-61912-4 (PMID: 32210245)

3. Blot S. Antiseptic mouthwash, the nitrate-nitrite-nitric oxide pathway, and hospital mortality. Intensive Care Med. 2020. DOI: 10.1007/s00134-020-06223-4

4. Schenkein HA, Loos BG, et al. Chlorhexidine mouthwash use and primary hypertension. Quintessence Int. 2025. PMID: 39639848

5. Bartsch S, Kohnert E, Kreutz C, Woelber JP, et al. Chlorhexidine digluconate alters oral microbiome and antibiotic resistance genes. Front Microbiol. 2024. DOI: 10.3389/fmicb.2024.1429692 (PMID: 38983634)

6. Van Strydonck DA, Timmerman MF, Van der Velden U, Van der Weijden GA. Plaque inhibition of two commercially available chlorhexidine mouthrinses. J Clin Periodontol. 2010. DOI: 10.1111/j.1600-0765.2010.01270.x (PMID: 20618550)

7. Escribano M, Herrera D, Morante S, et al. Efficacy of a low-concentration chlorhexidine mouth rinse in non-compliant periodontitis patients. J Clin Periodontol. 2013. DOI: 10.1111/jcpe.12014 (PMID: 22957711)

8. Bescos R, et al. Comparative effects of propolis and chlorhexidine on nitrite-producing bacteria and oral microbiome. Front Oral Health. 2024. PMID: 39691165